Molecular Development Specialist
Albany Med Health Systems
Dr. Christine Stellrecht received her B.S. in Medical Technology from the University of Buffalo and her Ph.D. from UT MD Anderson Cancer Center UTHealth Graduate School in Biomedical Sciences focusing on gene regulation and cancer biology. She completed a postdoctoral fellowship in the Department of Cell and Molecular Biology at Baylor College of Medicine focusing on gene regulation including embryonic development. Dr. Stellrecht joined The UT MD Anderson Cancer Center Faculty as a Research Associate in Dr. Grady Saunders laboratory in the Department of Biochemistry and Molecular Biology in 1996. She moved to the laboratory of Dr. Varsha Gandhi, Department of Experimental Therapeutics, UT MD Anderson Cancer Center where she applied her knowledge in molecular biology to embark her studies in translational research and moved up the ranks to Associate Professor. Much of her research career has focused on research in hematopoiesis and hematological malignancies. Dr. Stellrecht has published over 41 articles, was the PI or coPI on 12 institutional, national and international grants and is the recipient of 13 research awards. Moreover, Dr. Stellrecht played an instrumental role in developing the scientific premise for the extremely successful combination clinical trial of ibrutinib and venetoclax in chronic lymphocytic leukemia. In 2018, she retired from UT MD Anderson Cancer Center and in 2020 joined the Department of Clinical Pathology, Albany Medical Hospital, Albany NY where she is currently the Molecular Development Specialist in the Molecular Diagnostics Laboratory. Here she has developed and/or modified numerous diagnostics and quantitative molecular virology and oncology assays. Dr. Stellrecht holds her Certificate of Qualification in Oncology, Molecular and Cellular Tumor Markers from New York State Department of Health and is currently training to become an associate laboratory director of a Clinical Oncology Molecular Diagnostics Laboratory.